Drug discovery and development firm Immupharma on Thursday revealed that its pre-clinical work on P140, a peptide being developed as a Lupus treatment, may have other potential indications. The AIM-quoted company said the study yielded positive results for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a relapsing-remitting autoimmune-mediated inflammatory disease of the peripheral nervous system for which treatments are still lacking. Effects of the disease include ...Den vollständigen Artikel lesen ...